Genzon Investment Group (“Genzon Group”) was founded in December, 2003. Today, it has gradually evolved into an integrated enterprise group that combines six business units of real estate, pharmaceuticals, high-end services, new material development, sheet metal manufacturing and cold chain logistics. It is headquartered in Shenzhen, China and employs over 4,000 people.

Since its establishment, Genzon Group has successfully developed a variety of high-end projects, including high-end office buildings, boutique residential buildings, hotels, and golf clubs. It currently has a portfolio consisting of above 3 million square meters of completed properties (including 1 million square meters of self-owned properties) and over 2 million square meters of properties under development, shaping Genzon’s leading advantages in the development and operations of commercial real estate properties.

Genzon Pharmaceuticals Group (wholly owned by Genzon Group) emerged from Shenzhen Kexing Biotech Co., Ltd. which was founded in 1989. Genzon Pharmaceuticals Group’s main product brands include Recombinant Human Interferon α1b for Injection (SINOGEN), Recombinant Human Erythropoietin (EPOSINO), Recombinant Human Granulocyte (WHITE-C), Clostridium Butyricum (CHANGLEKANG) and etc. All rank top among similar products domestic and abroad in terms of market share, brand recognition and reputation. It has basically achieved diversified all-around development and exploitment in the pharmaceutical industry.

Genzon Group is fully aware of the tremendous space of growth in China’s profound urbanization process and obtains pioneering assessment of the increasing health-related demand in Chinese people. Centered around its core strategies of ‘highly market-oriented, highly professional, and highly specialized’ and backed by its real estate and pharmaceuticals platforms, Genzon Group will excavate deep in the burgeoning industrial forms of high-end services, new material development, sheet metal manufacturing and cold chain logistics, etc.

Genzon repositioned itself to “create a remarkable Value Ecosphere”. It continuously strives to be the industry leader and a trustworthy benchmarking corporation.